Arcoma (ARCOMA) Q2 2026 earnings summary

Executive summary

• Achieved stable performance in Q2 2026 with net sales of 31.6 MSEK, up slightly year-over-year, and continued profitability despite a cautious market environment.

• North America drove growth with a 16% sales increase, offsetting a 3% decline in Europe and a 43% drop in Asia.

• Launched a new 3D camera for Precision i5 and secured a significant US order for seven X-ray systems valued at 8 MSEK.

• Maintained a strong financial position with no interest-bearing debt and 30.9 MSEK in cash at quarter-end.

Financial highlights

• Q2 2026 net sales: 31,597 KSEK (31,378 KSEK Q2 2025); EBITDA: 1,269 KSEK (1,901 KSEK); EBIT: 305 KSEK (19 KSEK).

• Pre-tax profit: 396 KSEK (5 KSEK); EPS: 0.02 SEK (0.00 SEK).

• H1 2026 net sales: 62,727 KSEK (66,253 KSEK H1 2025); EBITDA: 3,744 KSEK (6,360 KSEK); pre-tax profit: 1,418 KSEK (2,587 KSEK); EPS: 0.08 SEK (0.16 SEK).

• Gross margin for Q2: 38% (39% Q2 2025).

• Cash flow from operations in Q2: -2,134 KSEK (7,849 KSEK Q2 2025), mainly due to increased receivables.

Outlook and guidance

• Underlying market drivers remain strong, with delayed investment projects expected to resume.

• Focus remains on accelerating sales, product innovation, and leveraging a scalable business model for long-term value.